Publikation: Canagliflozin mediated dual inhibition of mitochondrial glutamate dehydrogenase and complex I : an off-target adverse effect
Dateien
Datum
Herausgeber:innen
ISSN der Zeitschrift
Electronic ISSN
ISBN
Bibliografische Daten
Verlag
Schriftenreihe
Auflagebezeichnung
URI (zitierfähiger Link)
DOI (zitierfähiger Link)
Internationale Patentnummer
Link zur Lizenz
Angaben zur Forschungsförderung
Projekt
Open Access-Veröffentlichung
Sammlungen
Core Facility der Universität Konstanz
Titel in einer weiteren Sprache
Publikationstyp
Publikationsstatus
Erschienen in
Zusammenfassung
Recent FDA Drug Safety Communications report an increased risk for acute kidney injury in patients treated with the gliflozin class of sodium/glucose co-transport inhibitors indicated for treatment of type 2 diabetes mellitus. To identify a potential rationale for the latter, we used an in vitro human renal proximal tubule epithelial cell model system (RPTEC/TERT1), physiologically representing human renal proximal tubule function. A targeted metabolomics approach, contrasting gliflozins to inhibitors of central carbon metabolism and mitochondrial function, revealed a double mode of action for canagliflozin, but not for its analogs dapagliflozin and empagliflozin. Canagliflozin inhibited the glutamate dehydrogenase (GDH) and mitochondrial electron transport chain (ETC) complex I at clinically relevant concentrations. This dual inhibition specifically prevented replenishment of tricarboxylic acid cycle metabolites by glutamine (anaplerosis) and thus altered amino acid pools by increasing compensatory transamination reactions. Consequently, canagliflozin caused a characteristic intracellular accumulation of glutamine, glutamate and alanine in confluent, quiescent RPTEC/TERT1. Canagliflozin, but none of the classical ETC inhibitors, induced cytotoxicity at particularly low concentrations in proliferating RPTEC/TERT1, serving as model for proximal tubule regeneration in situ. This finding is testimony of the strong dependence of proliferating cells on glutamine anaplerosis via GDH. Our discovery of canagliflozin-mediated simultaneous inhibition of GDH and ETC complex I in renal cells at clinically relevant concentrations, and their particular susceptibility to necrotic cell death during proliferation, provides a mechanistic rationale for the adverse effects observed especially in patients with preexisting chronic kidney disease or previous kidney injury characterized by sustained regenerative tubular epithelial cell proliferation.
Zusammenfassung in einer weiteren Sprache
Fachgebiet (DDC)
Schlagwörter
Konferenz
Rezension
Zitieren
ISO 690
SECKER, Philipp Fabian, Sascha BENEKE, Nadja SCHLICHENMAIER, Johannes DELP, Simon GUTBIER, Marcel LEIST, Daniel R. DIETRICH, 2018. Canagliflozin mediated dual inhibition of mitochondrial glutamate dehydrogenase and complex I : an off-target adverse effect. In: Cell death & disease. 2018, 9(2), 226. eISSN 2041-4889. Available under: doi: 10.1038/s41419-018-0273-yBibTex
@article{Secker2018-02-14Canag-41619, year={2018}, doi={10.1038/s41419-018-0273-y}, title={Canagliflozin mediated dual inhibition of mitochondrial glutamate dehydrogenase and complex I : an off-target adverse effect}, number={2}, volume={9}, journal={Cell death & disease}, author={Secker, Philipp Fabian and Beneke, Sascha and Schlichenmaier, Nadja and Delp, Johannes and Gutbier, Simon and Leist, Marcel and Dietrich, Daniel R.}, note={Article Number: 226} }
RDF
<rdf:RDF xmlns:dcterms="http://purl.org/dc/terms/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:bibo="http://purl.org/ontology/bibo/" xmlns:dspace="http://digital-repositories.org/ontologies/dspace/0.1.0#" xmlns:foaf="http://xmlns.com/foaf/0.1/" xmlns:void="http://rdfs.org/ns/void#" xmlns:xsd="http://www.w3.org/2001/XMLSchema#" > <rdf:Description rdf:about="https://kops.uni-konstanz.de/server/rdf/resource/123456789/41619"> <dc:language>eng</dc:language> <dc:creator>Schlichenmaier, Nadja</dc:creator> <dcterms:isPartOf rdf:resource="https://kops.uni-konstanz.de/server/rdf/resource/123456789/28"/> <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2018-02-27T14:42:49Z</dc:date> <dc:creator>Leist, Marcel</dc:creator> <dc:creator>Delp, Johannes</dc:creator> <dcterms:available rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2018-02-27T14:42:49Z</dcterms:available> <dc:creator>Beneke, Sascha</dc:creator> <dc:creator>Gutbier, Simon</dc:creator> <dcterms:hasPart rdf:resource="https://kops.uni-konstanz.de/bitstream/123456789/41619/1/Secker_2-1qyoy8xzc1rka6.pdf"/> <dc:contributor>Delp, Johannes</dc:contributor> <dc:creator>Dietrich, Daniel R.</dc:creator> <dc:contributor>Beneke, Sascha</dc:contributor> <dcterms:title>Canagliflozin mediated dual inhibition of mitochondrial glutamate dehydrogenase and complex I : an off-target adverse effect</dcterms:title> <dc:contributor>Gutbier, Simon</dc:contributor> <dc:contributor>Dietrich, Daniel R.</dc:contributor> <dc:creator>Secker, Philipp Fabian</dc:creator> <foaf:homepage rdf:resource="http://localhost:8080/"/> <dspace:hasBitstream rdf:resource="https://kops.uni-konstanz.de/bitstream/123456789/41619/1/Secker_2-1qyoy8xzc1rka6.pdf"/> <dcterms:issued>2018-02-14</dcterms:issued> <dcterms:abstract xml:lang="eng">Recent FDA Drug Safety Communications report an increased risk for acute kidney injury in patients treated with the gliflozin class of sodium/glucose co-transport inhibitors indicated for treatment of type 2 diabetes mellitus. To identify a potential rationale for the latter, we used an in vitro human renal proximal tubule epithelial cell model system (RPTEC/TERT1), physiologically representing human renal proximal tubule function. A targeted metabolomics approach, contrasting gliflozins to inhibitors of central carbon metabolism and mitochondrial function, revealed a double mode of action for canagliflozin, but not for its analogs dapagliflozin and empagliflozin. Canagliflozin inhibited the glutamate dehydrogenase (GDH) and mitochondrial electron transport chain (ETC) complex I at clinically relevant concentrations. This dual inhibition specifically prevented replenishment of tricarboxylic acid cycle metabolites by glutamine (anaplerosis) and thus altered amino acid pools by increasing compensatory transamination reactions. Consequently, canagliflozin caused a characteristic intracellular accumulation of glutamine, glutamate and alanine in confluent, quiescent RPTEC/TERT1. Canagliflozin, but none of the classical ETC inhibitors, induced cytotoxicity at particularly low concentrations in proliferating RPTEC/TERT1, serving as model for proximal tubule regeneration in situ. This finding is testimony of the strong dependence of proliferating cells on glutamine anaplerosis via GDH. Our discovery of canagliflozin-mediated simultaneous inhibition of GDH and ETC complex I in renal cells at clinically relevant concentrations, and their particular susceptibility to necrotic cell death during proliferation, provides a mechanistic rationale for the adverse effects observed especially in patients with preexisting chronic kidney disease or previous kidney injury characterized by sustained regenerative tubular epithelial cell proliferation.</dcterms:abstract> <dc:rights>Attribution 4.0 International</dc:rights> <dc:contributor>Leist, Marcel</dc:contributor> <bibo:uri rdf:resource="https://kops.uni-konstanz.de/handle/123456789/41619"/> <dcterms:rights rdf:resource="http://creativecommons.org/licenses/by/4.0/"/> <dspace:isPartOfCollection rdf:resource="https://kops.uni-konstanz.de/server/rdf/resource/123456789/28"/> <dc:contributor>Schlichenmaier, Nadja</dc:contributor> <dc:contributor>Secker, Philipp Fabian</dc:contributor> <void:sparqlEndpoint rdf:resource="http://localhost/fuseki/dspace/sparql"/> </rdf:Description> </rdf:RDF>